POPULARITY
73 episodes with monotherapy
8 episodes with monotherapy
6 episodes with monotherapy
5 episodes with monotherapy
3 episodes with monotherapy
4 episodes with monotherapy
4 episodes with monotherapy
5 episodes with monotherapy
7 episodes with monotherapy
Welcome to the Hot Topics podcast from NB Medical with Dr Neal Tucker. Lots going on in this new episode! Three new pieces of research and an interview with Dr Anna Martinez, consultant paediatric dermatologist at GOSH, talking about a skin fragility condition many of us may not have heard of before - epidermolysis bullosa - in conjunction with DEBRA, the leading charity for EB awareness and research. In research, we look at two papers published this week in finerenone. Does it have a role in CKD management in patients without diabetes, and if so, how good is it?Second, retatruide - the latest injectable weight loss medication making a splash across the headlines - could it be used as monotherapy for recent onset type 2 diabetes?ResourcesNB Medical Epidermolysis bullosa free online educational moduleDEBRANEJM Finerenone for CKDLancet Finerenone MALancet Retatrutide for early T2DMwww.nbmedical.com/podcast
LBCT: Efficacy And Safety of Clopidogrel Versus Aspirin Monotherapy Beyond 12 Months After PCI In Patients at High Risk of Subsequent Cardiovascular Event
Next steps for major depressive disorder (MDD): master the latest clinical data on augmentation and switching strategies. Credit available for this activity expires: 4/29/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/when-monotherapy-fails-depression-evidence-based-update-2026a1000d6q?ecd=bdc_podcast_libsyn_mscpedu
Clopidogrel Monotherapy in Chronic Coronary Artery Disease Guest: Keri Zieminski, APRN, C.N.P., D.N.P. Host: Sharonne Hayes, M.D. This episode of Mayo Clinic's “Interviews With the Experts” will give an overview of clopidogrel monotherapy in patients with chronic CAD that are not on anticoagulation. Discussion will include why there has been a shift towards redefining antiplatelet medical therapy for this patient population, brief overview of recent trials, and how to manage a patient on clopidogrel monotherapy that needs to undergo noncardiac surgery. Topics Discussed: Why has there been a shift towards redefining antiplatelet medical therapy in patients with chronic CAD? What's changed? Recently published trials that highlight clopidogrel monotherapy. What is your process for managing a patient on clopidogrel monotherapy that needs to go for noncardiac surgery? Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on Twitter @MayoClinicCV and @MayoCVservices. LinkedIn: Mayo Clinic Cardiovascular Services Cardiovascular Education App: The Mayo Clinic Cardiovascular CME App is an innovative educational platform that features cardiology-focused continuing medical education wherever and whenever you need it. Use this app to access other free content and browse upcoming courses. Download it for free in Apple or Google stores today! No CME credit offered for this episode. Podcast episode transcript found here.
Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy
In this episode, editor in chief Joseph E. Safdieh, MD, FAAN, highlights articles about the benefit of shunts in idiopathic normal-pressure hydrocephalus, how neurologists drive downstream revenue, and anticoagulant monotherapy after stroke.
Anticoagulation Monotherapy in Patients with Chronic Coronary Artery Disease and Atrial Fibrillation Guest: Keri Zieminski, APRN, C.N.P., D.N.P. Host: Sharonne Hayes, M.D. This episode of Mayo Clinic's “Interviews With the Experts” will give an overview of anticoagulation monotherapy in patients with chronic CAD and atrial fibrillation. Discussion will include a brief overview of recently published trials that highlight the use of anticoagulation monotherapy in chronic CAD with atrial fibrillation, and how to manage a patient on anticoagulation monotherapy that needs to undergo noncardiac surgery. Topics Discussed: Why has there been a shift towards redefining antithrombotic medical therapy in patients with chronic CAD with atrial fibrillation? What's changed? Recently published trials that highlight the use of anticoagulation monotherapy in the chronic CAD + AF population. What is your process for managing a patient on anticoagulation monotherapy that needs to go for noncardiac surgery? Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on Twitter @MayoClinicCV and @MayoCVservices. LinkedIn: Mayo Clinic Cardiovascular Services Cardiovascular Education App: The Mayo Clinic Cardiovascular CME App is an innovative educational platform that features cardiology-focused continuing medical education wherever and whenever you need it. Use this app to access other free content and browse upcoming courses. Download it for free in Apple or Google stores today! No CME credit offered for this episode. Podcast episode transcript found here.
Arnon Kater joins Daniela Marin of The Lancet Haematology to discuss the phase 1b/2 EPCORE CLL-1 trial of epcoritamab monotherapy for Richter transformation, which is being presented at ASH 2025.Click here to read the full article: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00327-8/fulltextContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
In this episode, we explore evidence-based strategies for augmenting lithium when monotherapy fails in acute mania. Why is quetiapine the preferred add-on to valproate, despite decades of clinical tradition favoring anticonvulsants? Faculty: David Osser, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: An Update on Bipolar Mania Algorithm Augmenting With SGAs After Unsatisfactory Response to Lithium in Bipolar Mania
In this episode, we explore the critical decision of when to add lithium or valproate to second-generation antipsychotics in mixed manic episodes. Should you rush to combination therapy under managed care pressure, or does patience with strategic benzodiazepine bridging lead to better outcomes? Faculty: David Osser, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CMEs: An Update on Bipolar Mania Algorithm Choosing Between Valproate or Lithium Augmentation for Bipolar Mania With Mixed Features
Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality. While the development of targeted therapies has improved outcomes for many patients with EGFR-mutated NSCLC, those with rare EGFR variants often face limited treatment options, especially when the disease involves the central nervous system (CNS). A recent research paper, titled “Durable complete response in leptomeningeal disease of EGFR mutated non-small cell lung cancer to amivantamab, an EGFR-MET receptor bispecific antibody, after progressing on osimertinib” published in Volume 16 of Oncotarget, describes a patient with NSCLC harboring two uncommon EGFR mutations—G719A and A289V—who experienced a prolonged and clinically significant response to amivantamab monotherapy, after prior treatments had failed. Full blog - https://www.oncotarget.org/2025/08/26/amivantamab-monotherapy-in-rare-egfr-mutated-advanced-nsclc/ Paper DOI - https://doi.org/10.18632/oncotarget.28730 Correspondence to - Young Kwang Chae - young.chae@northwestern.edu Video short - https://www.youtube.com/watch?v=UEiCz834a8c Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28730 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, amivantamab, monotherapy, rare EGFR mutation, NSCLC, leptomeningeal disease About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM
CME credits: 1.00 Valid until: 25-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/clinical-evidence-on-monotherapy-with-menin-inhibitors-in-rr-aml/36180/ This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.
CME credits: 1.00 Valid until: 25-07-2026 Claim your CME credit at https://reachmd.com/programs/cme/clinical-evidence-on-monotherapy-with-menin-inhibitors-in-rr-aml/36180/ This online CME activity explores the evolving treatment landscape of acute myeloid leukemia (AML), emphasizing the importance of molecular profiling and risk stratification to guide precision therapy. Experts discuss guideline-based strategies for treatment sequencing and review recent data on menin-directed therapies. In addition, the program reviews approaches for monitoring and managing adverse events associated with menin inhibitors, including balancing therapeutic benefit and quality of life. It also highlights clinical trial opportunities and the importance of shared decision-making to enhance patient outcomes.
Join Professor Iain McInnes and Professor Rieke Alten for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest updates in RA. In this episode, they discuss three papers: the impact of TOF treatment on weight and BMI in RA patients, to that of alternate treatment options for RA patients with prior MTX-inadequate response, and the treatment of JAKis versus TNFis in RA.
Hosts Mitsuaki Sawano, MD, Kentaro Ejiri, MD, and Nobuhiro Ikemura, MD, welcome Yuki Obayashi, MD, of Leiden University Medical Center, to discuss findings from the STOPDAPT-3 trial. Dr. Obayashi highlights that, among ACS patients—including those with HBR or STEMI—aspirin and clopidogrel monotherapy after 1 month of DAPT resulted in similar rates of ischemic and bleeding events. These results support flexible, patient-centered antiplatelet strategies beyond the acute phase.
BUFFALO, NY - June 11, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on May 29, 2025, titled “Durable complete response in leptomeningeal disease of EGFR mutated non-small cell lung cancer to amivantamab, an EGFR-MET receptor bispecific antibody, after progressing on osimertinib.” A team led by first author Jinah Kim, from the University of Vermont Medical Center, and corresponding author Young Kwang Chae, from the Feinberg School of Medicine, reports a clinical case in which a patient with advanced non-small cell lung cancer (NSCLC) carrying rare EGFR mutations responded remarkably to amivantamab after other treatments had failed. The patient experienced a complete resolution of brain and spinal fluid metastases, suggesting that amivantamab may be a viable option for patients with uncommon genetic profiles and limited therapy options. Lung cancer remains one of the leading causes of cancer-related deaths worldwide. Patients with NSCLC who have rare mutations in the EGFR gene often face limited treatment options and poor outcomes, especially when the disease spreads to the brain or spinal fluid. This case involved a 67-year-old man diagnosed with NSCLC who had two rare EGFR mutations—G719A and A289V. After disease progression on osimertinib and other therapies, the patient began amivantamab monotherapy. Within six weeks, his lung tumor shrank by over 30 percent. By six months, imaging confirmed the disappearance of brain metastases and leptomeningeal disease, a serious condition affecting the membranes of the brain and spinal cord. Blood tests showed no detectable cancer-related mutations, and the patient, previously wheelchair-bound, regained the ability to walk and perform daily activities. This response has been sustained for more than 19 months. “Treatment produced a durable response over 19 months, including a 32.2% reduction in tumor size at six weeks, and complete resolution of brain metastases and LMD by six months.” Amivantamab is a bispecific antibody that targets EGFR and MET, two key drivers of tumor growth. While it is approved in combination regimens for common EGFR mutations, its effectiveness as a single agent in rare mutations or in treating brain metastases remains largely unproven. This case challenges the assumption that large antibody drugs cannot cross the blood-brain barrier and suggests that amivantamab may have potential in managing central nervous system involvement. Further research is needed to clarify how the drug achieves these effects and to explore its broader use in patients with rare EGFR mutations and limited treatment options. This case highlights three key findings: amivantamab may be effective against rare EGFR mutations, can be used as monotherapy, and may overcome the challenges of the blood-brain barrier. Although based on a single patient, the results provide encouraging evidence to support further investigation of amivantamab in treating difficult-to-manage forms of NSCLC. DOI - https://doi.org/10.18632/oncotarget.28730 Correspondence to - Young Kwang Chae - young.chae@northwestern.edu Video short - https://www.youtube.com/watch?v=RJX3rmtH7h8 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, amivantamab, monotherapy, rare EGFR mutation, NSCLC, leptomeningeal disease To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM
Clopidogrel Versus Aspirin for Long-term Maintenance Monotherapy in Patients with High Ischemic Risk After Percutaneous Coronary Intervention
Joe Jacob joins the show to discuss the longer-term follow up of this cohort from SunRISe-1. We discuss definitions of CR and regulatory issues around drug approval in this space as well.
Watch Here : https://www.youtube.com/watch?v=qp48ZCMHjBE Website: https://vigoroussteve.com/ Consultations: https://vigoroussteve.com/consultations/ eBooks: https://vigoroussteve.com/shop/ YouTube Channel: http://www.youtube.com/user/VigorousSteve/ Workout Clips Channel: https://www.youtube.com/channel/UCWi2zZJwmQ6Mqg92FW2JbiA Instagram: https://instagram.com/vigoroussteve/ TikTok: https://www.tiktok.com/@vigoroussteve Reddit: https://www.reddit.com/r/VigorousSteve/ PodBean: https://vigoroussteve.podbean.com/ Spotify: https://open.spotify.com/show/2wR0XWY00qLq9K7tlvJ000 Patreon: https://www.patreon.com/vigoroussteve
In today's episode, supported by Takeda, we had the pleasure of speaking with Ibrahim T. Aldoss, MD, and Elias Jabbour, MD, about the use of ponatinib (Iclusig) monotherapy after combination chemotherapy in patients with newly diagnosed Philadelphia chromosome–positive (Ph)–positive acute lymphoblastic leukemia (ALL). Dr Aldoss is an associate professor in the Division of Leukemia in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope in Duarte, California. Jabbour is a professor in the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston. In our exclusive interview, Drs Aldoss and Jabbour discussed findings from a post hoc subgroup analysis of the phase 3 PhALLCON trial (NCT03589326) that support the use of ponatinib monotherapy following combination treatment with a TKI plus chemotherapy in patients with newly diagnosed Ph-positive ALL, safety considerations when using ponatinib in this patient population, and how findings from this subgroup analysis may affect transplantation rates in this disease.
Ozempic gains expanded approval; MS treatment gets Boxed Warning added to label; Monotherapy approval granted for treatment resistant depression Tx Spravato; Leqembi gains maintenance regimen; Enhertu gains new Breast CA indication.
CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/clinical-evidence-driving-guideline-recommendations-for-monotherapy-in-the-second-line-or-later-setting-in-metastatic-urothelial-cancer/29194/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.
CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/clinical-evidence-driving-guideline-recommendations-for-monotherapy-in-the-second-line-or-later-setting-in-metastatic-urothelial-cancer/29194/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.
In this episode, Dr. Valentin Fuster discusses the ASSURE DES trial, which compared aspirin monotherapy to withholding antiplatelet therapy in stable patients with drug-eluting stents undergoing non-cardiac surgery. The trial found no significant difference in major adverse outcomes between the two strategies, though minor bleeding was more common in the aspirin group, leading to a recommendation to continue aspirin therapy for most patients undergoing low-to-intermediate risk surgery, with exceptions for those at high bleeding risk.
In this episode, Dr. Valentin Fuster reviews two pivotal phase three trials from China assessing the efficacy of the new monoclonal antibody, Katisha, for treating non-familial hypercholesterolemia. With significant reductions in LDL cholesterol and a long-acting, flexible dosing regimen, these studies promise a novel therapeutic option for patients struggling with cholesterol management and adherence to traditional treatments.
Betrand Tombal joins Brian and Tom to discuss the historic and current data for AR inhibition with monotherapy with AR blockers.
Send us a textClonidine as Monotherapy for Neonatal Opioid Withdrawal Syndrome: A Randomized Trial.Bada HS, Westgate PM, Sithisarn T, Yolton K, Charnigo R, Pourcyrous M, Tang F, Gibson J, Shearer-Miller J, Giannone P, Leggas M.Pediatrics. 2024 Oct 15:e2023065610. doi: 10.1542/peds.2023-065610. Online ahead of print.PMID: 39403061As always, feel free to send us questions, comments, or suggestions to our email: nicupodcast@gmail.com. You can also contact the show through Instagram or Twitter, @nicupodcast. Or contact Ben and Daphna directly via their Twitter profiles: @drnicu and @doctordaphnamd. The papers discussed in today's episode are listed and timestamped on the webpage linked below. Enjoy!
34th ESC 2024: Ticagrelor monotherapy vs. dual antiplatelet therapy
Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, Daniel Ontaneda, MD, PhD, a staff member of the Cleveland Clinic Mellen Center for Multiple Sclerosis, provided an in-depth overview on the newly announced McDonald criteria to diagnose multiple sclerosis (MS). Ontaneda, who also serves as an assistant professor of neurology, discussed the most notable changes to the criteria and how it may help towards improving rates of misdiagnosis and missed diagnosis. He spoke on the incorporation of new biomarkers, such as central vein sign and paramagnetic rim lesions, and the ability to diagnose MS in stages before clinical presentation shows. Furthermore, Ontaneda gave some perspective on the areas of the new criteria that will take some time to adjust to, as well as how these criteria may change the philosophical perspective of the disease as a whole. Looking for more Multiple sclerosis discussion? Check out the NeurologyLive® multiple sclerosis clinical focus page. Episode Breakdown: 1:10 – Focus and direction of new diagnostic criteria 3:00 – Overviewing specific changes to McDonald criteria 10:50 – Approach to diagnosing pre-MS; treating radiologically isolated syndrome earlier 12:55 – Neurology News Minute 15:10 – Incorporation of new biomarkers, central vein sign, paramagnetic rim lesions, OCT 21:45 – Unanswered questions/challenges left out of the diagnostic criteria The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: Potential Regulatory Submission for Inebilizumab in Myasthenia Gravis Following Positive Phase 3 MINT Data Parkinson Agent Tavapadon Meets Primary and Secondary End Points as Monotherapy in Phase 3 TEMPO-1 Trial Sage Therapeutics and Biogen Officially Announce Ending of SAGE-324 Program in Essential Tremor Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.
Watch Here : https://www.youtube.com/watch?v=Vk5TjOG--8w Website: https://vigoroussteve.com/ Consultations: https://vigoroussteve.com/consultations/ eBooks: https://vigoroussteve.com/shop/ YouTube Channel: http://www.youtube.com/user/VigorousSteve/ Workout Clips Channel: https://www.youtube.com/channel/UCWi2zZJwmQ6Mqg92FW2JbiA Instagram: https://instagram.com/vigoroussteve/ TikTok: https://www.tiktok.com/@vigoroussteve Reddit: https://www.reddit.com/r/VigorousSteve/ PodBean: https://vigoroussteve.podbean.com/ Spotify: https://open.spotify.com/show/2wR0XWY00qLq9K7tlvJ000 Patreon: https://www.patreon.com/vigoroussteve
AUA2024: Contemporary Pharmacotherapy for OAB 2024: Monotherapy and Combined Pharmacotherapy to Optimize Treatment CME Available: https://auau.auanet.org/node/41048 At the conclusion of this activity, participants will be able to: 1. Define the similarities and differences between the various oral pharmacotherapies for overactive bladder (OAB) 2. Review the principles of physiology and pharmacotherapy for currently available agents including the antimuscarinics and beta-3 agonists. 3. Review the salient features as well as changes in the updated AUA/SUFU guideline on OAB 4. Analyze the clinical (and theoretical) advantages and limitations of currently available agents 5. Discuss potential future pharmacological pathways and therapies for OAB. ACKNOWLEDGEMENTS This educational activity is supported by independent educational grants from: Astellas
Featuring perspectives from Ms Jennifer Filipi, Ms Kathryn Lyle, Dr David O'Malley and Dr Shannon N Westin, including the following topics: Introduction (0:00) Incidence and Biology of Endometrial Cancer (EC) (9:30) Use of Immune Checkpoint Inhibitors as Monotherapy for EC (23:24) First-Line Therapy for Primary Advanced or Recurrent EC (28:28) Lenvatinib/Pembrolizumab in the Management of Metastatic EC (1:05:08) Potential Role of Selinexor in the Management of EC (1:13:20) Incidence and Management of HER2-Positive EC (1:22:51) NCPD information and select publications
Watch Here : https://www.youtube.com/watch?v=iwvsZR8diH8 Website: https://vigoroussteve.com/ Consultations: https://vigoroussteve.com/consultations/ eBooks: https://vigoroussteve.com/shop/ YouTube Channel: http://www.youtube.com/user/VigorousSteve/ Workout Clips Channel: https://www.youtube.com/channel/UCWi2zZJwmQ6Mqg92FW2JbiA Instagram: https://instagram.com/vigoroussteve/ TikTok: https://www.tiktok.com/@vigoroussteve Reddit: https://www.reddit.com/r/VigorousSteve/ PodBean: https://vigoroussteve.podbean.com/ Spotify: https://open.spotify.com/show/2wR0XWY00qLq9K7tlvJ000 Patreon: https://www.patreon.com/vigoroussteve
Ticagrelor Monotherapy in Patients with Acute Coronary Syndrome: An Individual Patient Data Meta-Analysis of Randomized TICO and T-PASS Trials
Impact: SAPT 1 year after PCI
Commentary by Dr. Valentin Fuster
In this podcast, Julie Ann Justo, PharmD, MS, FIDSA, BCPS, discusses treatment of carbapenem-resistant Enterobacterales (CRE) infections, including:Burden of CRE infections in the United StatesMechanisms of resistanceChanging epidemiologyUse of rapid diagnostic testsIDSA guidance recommendations, including supporting dataApproach to designing treatment regimens, including weighing patient- and infection-related factorsFaculty:Julie Ann Justo, PharmD, MS, FIDSA, BCPSClinical Pharmacist Lead – Infectious DiseasesInpatient PharmacyDartmouth Hitchcock Medical CenterLebanon, New HampshireLink to full program: https://bit.ly/41a8Mj0Link to accompanying ClinicalThought commentary:https://bit.ly/4865T57Link to downloadable infographic: https://bit.ly/3t7NpT2
This week we discuss the continued push to introduce 2nd generation androgen inhibitors earlier into treatment with the EMBARK trial. Nivolumab and pembrolizumab, pemrolizumab and nivolumab. Again and again. Their role (and approvals) for adjuvant melanoma make sense. But what to think about their use for NSCLC in the neoadjuvant setting? West commentary: https://dailynews.ascopubs.org/do/should-induction-chemoimmunotherapy-lead-us-broaden-our-definition-resectability-nsclc
Pim Aarts, MD interviewed by Olayemi Sokumbi, MD, FAAD
Watch Here : https://www.youtube.com/watch?v=Dabf89VAdWA Website: https://vigoroussteve.com/ Consultations: https://vigoroussteve.com/consultations/ eBooks: https://vigoroussteve.com/shop/ YouTube Channel: http://www.youtube.com/user/VigorousSteve/ Workout Clips Channel: https://www.youtube.com/channel/UCWi2zZJwmQ6Mqg92FW2JbiA Instagram: https://instagram.com/vigoroussteve/ TikTok: https://www.tiktok.com/@vigoroussteve Reddit: https://www.reddit.com/r/VigorousSteve/ PodBean: https://vigoroussteve.podbean.com/ Spotify: https://open.spotify.com/show/2wR0XWY00qLq9K7tlvJ000 Patreon: https://www.patreon.com/vigoroussteve
Commentary by Dr. Valentin Fuster
Commentary by Dr. Valentin Fuster
Acne might just be unmatched as an aesthetic concern for how visible and traumatizing it can be for patients. Yet truly significant improvements in acne treatments have been hard to come by. As Cutera SVP Steve Kreider notes in this interview with Dr. Grant Stevens, "I've been selling acne products for 17 years, and the standard of care hasn't fundamentally changed."Except that Cutera itself has now changed the game with AviClear, a laser treatment that offers a safe, prescription-free solution for acne. In addition to reducing existing acne, clinical trials show that future breakout episodes are shorter, less intense, and more infrequent following the AviClear procedure. Further, acne clearance results continue to improve over time, demonstrating the long-term efficacy of this novel treatment. Join us as Dr. Stevens explores all the details of this groundbreaking laser device, along with breaking news about a recent FDA clearance for AviClear, all on the latest episode of The Technology of Beauty.Show Notes:00:00 Intro00:27 Background06:53 Arrival at Cutera08:50 Treating acne with light-based technology09:47 Breaking news!11:54 Monotherapy vs. multi-factoral treatments13:24 Procedure description, patient comfort, recovery16:07 Off-face? Anesthetic? Cost?18:17 Discussion of the Cutera xeo, lasers, other devices23:10 The future of aestheticsAny statements or views expressed on this podcast are the opinion of the host and guest(s) respectively. The technologies and commercial products discussed herein, and any claims made in relation to these, have not been evaluated by the Technology of Beauty, its host, or producers. AviClear results may vary.» Apple Podcasts | https://podcasts.apple.com/us/podcast/technology-of-beauty/id1510898426» Spotify | https://open.spotify.com/show/0hEIiwccpZUUHuMhlyCOAm» Recent episodes | https://www.influxmarketing.com/technology-of-beauty/» Instagram | https://www.instagram.com/thetechnologyofbeauty/» LinkedIn | https://www.linkedin.com/company/the-technology-of-beauty/The Technology of Beauty is produced by Influx Marketing, The Digital Agency for Aesthetic Practices. https://www.influxmarketing.com/Want more aesthetic insights? Subscribe to Next Level Practices, the show where we discuss the ever-changing world of digital marketing and patient acquisition and bring you the latest ideas, strategies, and tactics to help you take your practice to the next level. https://www.influxmarketing.com/next-level-practices/
Several medication classes can be used to treat diabetic peripheral neuropathic pain (DPNP); however, many patients have a suboptimal response or experience dose-limiting side effects. Treatment guidelines suggest several first-line options but, in the absence of compelling evidence, offer no direction as to which agent to try first or if we should consider combination therapy. Guest Authors: Shilpa Klocke, PharmD, BCPS and Nicole Hahn, PharmD, BCACP Music by Good Talk
© 2020-2026 Ivy Podcast Discovery LLC
